Biomarkers in Alzheimer’s Disease: Advances in Detection and Clinical Translation

The field of Alzheimer’s disease (AD) research has evolved significantly, shifting from a sole reliance on clinical diagnosis to an integrated approach based on biological markers that reveal the earliest pathological changes. This paradigm shift underscores the importance of biomarkers not only for characterizing disease onset and progression, but also for guiding clinical trials and therapeutic strategies. Despite considerable advances, current challenges include the validation and standardization of biomarkers across diverse populations, ensuring accessibility, and understanding their relationship to the complex underlying mechanisms of AD. While various types of biomarkers—ranging from amyloid and tau pathologies to neuroinflammation, synaptic loss, and vascular contributions—have shown promise in early detection, there is an ongoing need to address knowledge gaps and discrepancies in biomarker performance due to genetic, demographic, and methodological differences.This Research Topic aims to highlight progress in the identification, validation, and application of biomarkers in Alzheimer’s disease, with a special focus on their translational value. We seek contributions that elucidate how biomarkers inform disease mechanisms, facilitate early and accurate diagnosis, and improve prognostication and treatment monitoring in AD. The collection also aims to evaluate the practicality of integrating biomarkers into clinical workflows, explore advances in blood-based and digital markers, and address issues such as ethical disclosure, standardization across platforms, and the impact of co-occurring conditions.This Research Topic encompasses a broad but defined range of inquiries, centered on current and emerging biomarkers in AD. It excludes research not directly related to Alzheimer’s or lacking clear translational relevance. To gather further insights into biomarkers in Alzheimer’s disease, we welcome articles addressing, but not limited to, the following themes:o Biomarker classification frameworks and staging across the AD continuumo Fluid biomarkers (e.g., CSF, plasma amyloid-β, tau proteins, neurofilament light, inflammatory markers) and their analytical challengeso Imaging markers (amyloid/tau PET, MRI modalities, emerging ligands) and quantification methodso Multi-omics approaches (proteomics, metabolomics, lipidomics, transcriptomics, epigenetics, spatially resolved analytics) for integrative biomarker discoveryo Digital and wearable technologies for non-invasive detection and monitoringo Contributions of comorbidities and pathological heterogeneity to biomarker performanceo Clinical trial applications, such as participant selection, therapeutic monitoring, and surrogate endpointso Considerations of equity, implementation, cost-effectiveness, and ethical communication of biomarker resultsWe invite original research articles, methods papers, brief reports, and reviews that advance the scientific and clinical understanding of biomarkers in Alzheimer’s disease. Topic editors: Valquiria Bueno, Tamas Fulop Source: https://www.frontiersin.org/research-topics/79566/biomarkers-in-alzheimers-disease-advances-in-detection-and-clinical-translation